Future Science Group
Browse
Supplemental_Tables1-2.docx (15.79 kB)

Supplementary Tables – Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives

Download (15.79 kB)
dataset
posted on 2022-03-07, 08:55 authored by Figshare Future Science GroupFigshare Future Science Group, Suvina Amin, Sara M. Tolaney, M. Janelle Cambron-Mellott, Kathleen Beusterien, Martine C. Maculaitis, Emily Mulvihill, Reshma Shinde, Kimmie McLaurin

Supplemental Table 1. Study attrition: patients.

Supplemental Table 2. Study attrition: oncologists.

Funding

AstraZeneca

Merck Sharp and Dohme

History